General
Preferred name
VELIPARIB
Synonyms
ABT-888 ()
NSC 737664 ()
ABT-888 dihydrochloride ()
Veliparib dihydrochloride ()
ABT 888 ()
ABT 888 dihydrochloride ()
ABT888 ()
UNII-01O4K0631N ()
Veliparib (dihydrochloride) ()
ABT-888 (Veliparib) ()
Veliparib (ABT-888) ()
PARP-1 INHIBITOR ABT-888 ()
ABT-888 (hydrochloride) ()
P&D ID
PD003637
CAS
912444-00-9
912445-05-7
Tags
available
drug candidate
probe
Drug indication
Ovarian cancer
Epithelial ovarian cancer
Melanoma
Breast cancer
Non-small-cell lung cancer
Drug Status
investigational
Max Phase
Phase 3
Probe info
Probe selectivity
family-selective
Probe type
P&D approved
calculated probe
experimental probe
Probe sources
Probe targets
[[ compound.targets[t].gene_name ]]
Probe control
Probe control not defined
Orthogonal probes
10
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
COMMENT
Velaparib is not overly potent in vivo as a a single agent but potentiates both chemo- and radiotherapy. Like other PARP inhibitors, veliparib is a potent inhibitor of PARP1 and 2 but not the other 15 family members. Critically, velparib appears to inhibit PARP as an inhibitor of catalytic function and does not enhance PARP trapping at the site of DNA damage. Given this, veliparib is strongly recommended for the deconvolution of the catalytic roles of PARP in in vitro experiments. Aug 5 2016 - 3:06pm; Veliparib is a PARP 1/2 inhibitor. This agent is an excellent tool to study PARP inhibition in both the cellular and in vivo setting. However, an important study about the mechanism of these probes appeared in 2012 (Murai et al., Cancer Res. 2012, 72, 5588-5599). In this study, the authors examined the ability of niraparib, olaparib and veliparib to trap PARP1/2 enzymes at the site of DNA damage as opposed to examining merely their activity as inhibitors of the catalytic function of the enzyme. The authors found that the cellular toxicity tracked with the trapping potential (which was different for each drug) rather than each drugs catalytic efficiency (which was similar for each drug). The ranking of each drug for trapping efficiency was found to be niraparib > olaparib >> veliparib. Investigators should thoroughly evaluate their needs when choosing the appropriate PARP inhibitor based upon this altered mechanistic insight. Sep 8 2016 - 11:36am; Veliparib is a potent dual PARP1/2 inhibitor. It is highly recommended for studying the function of these targets in vitro. Veliparib has also shown utility in in vivo studies and even some degree of CNS penetrance. Sep 9 2016 - 6:17pm; Veliparib is a PARP1/2 inhibitor with selectivity sufficient for cellular work to interrogate PARP1/2. While target engagement has been shown in vivo at modest doses, the lack of receptor profiling limits my recommendation for Veliparib to be used as an in vivo probe. Jan 18 2017 - 12:04pm
DESCRIPTION
Veliparib is an investigational poly ADP ribose polymerase (PARP) inhibitor. PARP inhibitors have potential for treating many diseases, including cancer.
(GtoPdb)
MOA
Catalytic inhibitor;PARP-DNA complex trapping
MOA
Catalytic inhibitor, PARP-DNA complex trapping
(Chemical Probes.org)
DESCRIPTION
inhibitor of poly (ADP-ribose) polymerase 1 (PARP1) and 2 (PARP2)
(Informer Set)
DESCRIPTION
Potent ADAM10 and ADAM17 inhibitor
(Tocris Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
149
Organisms
0
Compound Sets
24
Cayman Chemical Bioactives
ChEMBL Drugs
Chemical Probes.org
Drug Repurposing Hub
DrugBank
DrugMAP
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
High-quality chemical probes
Informer Set
LINCS compound set
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
Tocris Bioactive Compound Library
Tool Compound Set
Welcome Trust Cancer Drugs
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
46
Molecular Weight
244.13
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
3
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
2
cLogP
1.26
TPSA
83.8
Fraction CSP3
0.38
Chiral centers
1.0
Largest ring
6.0
QED
0.74
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
PARP1
PARP2
PARP1, PARP2
Poly [ADP-ribose] polymerase-1
Poly [ADP-ribose] polymerase 2
Apoptosis related,Autophagy,PARP
Compound status
clinical
Pathway
Genome integrity
Chromatin/Epigenetic
DNA Damage/DNA Repair
Autophagy
Cell Cycle/DNA Damage
Epigenetics
Primary Target
Poly(ADP-ribose) Polymerase
MOA
PARP
Inhibitor
PARP inhibitor
Member status
member
Target class
Other post-translational modification
Other post-translational modification, Other post-translational modification
Orthogonal probe
Olaparib
Target subclass
PARP, PARP
Source data
